Use of chronic medications among a large, commercially-insured US population

被引:13
|
作者
Roe, CM
McNamara, AM
Motheral, BR
机构
[1] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA
[2] Express Scripts Inc, Womens Hlth, Maryland Hts, MO 63043 USA
[3] Express Scripts Inc, Outcomes Res, Maryland Hts, MO USA
关键词
chronic medication use; gender differences; sex differences; pharmacy claim database;
D O I
10.1002/pds.700
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose To examine use of chronic therapies by females and males of all ages. Methods Participants were 1295 948 members of a large US pharmacy benefit manager. The use of chronic medications by males and females during 1999 was examined overall and within 16 commonly-used chronic drug groups. Dependent variables were use of a drug group, number of drug groups used, number of prescriptions filled and sum of costs, both within each drug group and overall, Combination therapy was defined as using at least two of the 16 chronic therapy groups during 1999. Results Females were more likely than males to use chronic medications during the study year (36.5 vs. 22.4%, p < 0.001). Generally, the likelihood of using a chronic medication increased with age for both sexes. Commonly-used chronic medications accounted for 54 and 50% of prescriptions for females and males respectively, and for 53% of total drug costs for both sexes. There were few meaningful sex differences in the likelihood of using particular drug groups. Of those who took chronic drugs 14% used combination chronic therapy. Conclusions This study provides demographic information regarding treatment of chronic conditions that can be used to aid policy decisions and to provide an impetus for future research. Copyright (C) 2002 John Wiley & Sons, Ltd.
引用
收藏
页码:301 / 309
页数:9
相关论文
共 50 条
  • [1] USE OF NARCOTIC MEDICATIONS AMONG A LARGE COMMERCIALLY-INSURED POPULATION IN THE UNITED STATES
    Tian, Y.
    Henderson, R. R.
    Frazee, S. G.
    VALUE IN HEALTH, 2012, 15 (04) : A108 - A108
  • [2] Epidemiology and treatment of chronic kidney disease among commercially-insured patients in the US
    Kauf, T.
    Wang, W.
    Dillon, A.
    Mikulski, H.
    Singh, I.
    Odegard, J.
    Ringemann, C.
    Haldrup, S.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S143 - S143
  • [3] Off-Label Use of Antipsychotics among US Commercially-Insured Youth
    Hong, Kyungwan
    Spence, O'Mareen
    dosReis, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 40 - 41
  • [4] Changing patterns of use of implantable cardiac monitors from 2011 to 2018 for a large commercially-insured US population
    Ellenbogen, Michael, I
    Andersen, Kathleen M.
    Marine, Joseph E.
    Wang, Nae-Yuh
    Segal, Jodi B.
    MEDICINE, 2021, 100 (51) : E28356
  • [5] PREVALENCE OF CHRONIC HEPATITIS C VIRUS AND COMMONLY-ASSOCIATED COMORBIDITIES WITHIN A LARGE US COMMERCIALLY-INSURED POPULATION
    Scaife, J.
    Kuti, E.
    Acampa, L.
    Million, R.
    Miyasato, G.
    Wang, Z.
    Sander, S.
    Sanchez, H.
    Kokkotos, F. K.
    VALUE IN HEALTH, 2013, 16 (03) : A82 - A83
  • [6] PREVALENCE AND INCIDENCE OF ACUTE UROGENITAL CONDITIONS IN A US COMMERCIALLY-INSURED POPULATION
    Li, Q.
    Wu, N.
    Lee, E.
    Sullivan, P. W.
    VALUE IN HEALTH, 2013, 16 (03) : A158 - A158
  • [7] Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population
    Esposito, Daina
    Titievsky, Lina
    Beachler, Daniel C.
    Hawes, Jennifer C. L.
    Isturiz, Raul
    Scott, Daniel A.
    Gangemi, Kelsey
    Maroko, Robert
    Hall-Murray, Cassandra K.
    Lanes, Stephan
    VACCINE, 2018, 36 (52) : 8084 - 8093
  • [8] Comorbidity Burden of Chronic Hepatitis B in a Commercially-insured Population in the United States
    Juday, Timothy
    Johnston, Stephen S.
    Wilson, Kathleen
    Quadri, Syed
    HEPATOLOGY, 2013, 58 : 624A - 624A
  • [9] Psychotropic prevalence among a US commercially-insured youth: 2007-2015
    Hong, Kyungwan
    Spence, O'Mareen
    dos Reis, Susan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 167 - 168
  • [10] Burden of illness among patients with Alzheimer's disease in a commercially-insured population
    Zhao, Y
    Bowman, L
    Flynn, JA
    Joyce, AT
    Carter, CT
    Ollendorf, DA
    VALUE IN HEALTH, 2006, 9 (03) : A68 - A69